Literature DB >> 28399406

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle.

Matthew J Schiewer1, Karen E Knudsen2.   

Abstract

In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed "cell-cycle-targeting miRNAs," that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis. These miRNAs effectively suppressed chemoresistant patient-derived xenograft growth in vivo, and efficacy could be prospectively predicted with an expression-based algorithm.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28399406      PMCID： PMC5709809          DOI： 10.1016/j.ccell.2017.03.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Identification of novel genes coding for small expressed RNAs.

Authors:  M Lagos-Quintana; R Rauhut; W Lendeckel; T Tuschl
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

2.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Jungsil Ro; Fabrice André; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Cynthia Huang Bartlett; Ke Zhang; Carla Giorgetti; Sophia Randolph; Maria Koehler; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-06-01       Impact factor: 91.245

Review 3.  Targeting noncoding RNAs in disease.

Authors:  Brian D Adams; Christine Parsons; Lisa Walker; Wen Cai Zhang; Frank J Slack
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

4.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Authors:  Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

Review 5.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.

Authors:  Per Hydbring; Yinan Wang; Anne Fassl; Xiaoting Li; Veronica Matia; Tobias Otto; Yoon Jong Choi; Katharine E Sweeney; Jan M Suski; Hao Yin; Roman L Bogorad; Shom Goel; Haluk Yuzugullu; Kevin J Kauffman; Junghoon Yang; Chong Jin; Yingxiang Li; Davide Floris; Richard Swanson; Kimmie Ng; Ewa Sicinska; Lars Anders; Jean J Zhao; Kornelia Polyak; Daniel G Anderson; Cheng Li; Piotr Sicinski
Journal:  Cancer Cell       Date:  2017-04-10       Impact factor: 31.743

8.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors:  Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Clinical applications of microRNAs.

Authors:  Per Hydbring; Gayane Badalian-Very
Journal:  F1000Res       Date:  2013-06-06
  10 in total
  3 in total

Review 1.  MYC Modulation around the CDK2/p27/SKP2 Axis.

Authors:  Per Hydbring; Alina Castell; Lars-Gunnar Larsson
Journal:  Genes (Basel)       Date:  2017-06-30       Impact factor: 4.096

2.  Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma.

Authors:  Tian-Geng He; Zi-Yun Xiao; Yi-Qiao Xing; Hua-Jing Yang; Hong Qiu; Jian-Bin Chen
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

3.  Inhibition of lung cancer growth and metastasis by DHA and its metabolite, RvD1, through miR-138-5p/FOXC1 pathway.

Authors:  Xiaoming Bai; Jiaofang Shao; Sujin Zhou; Zhenggang Zhao; Fanghong Li; Rong Xiang; Allan Z Zhao; Jinshun Pan
Journal:  J Exp Clin Cancer Res       Date:  2019-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.